RxDoctor Payments Data

Balkrishna Singh, MD

Cardiovascular Disease · Little Rock, ARNPI 1639125222

Payments from drug & device makers

$1,980in general payments, 2019–2025

Across 138 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$986
  • E.r. Squibb & Sons, L.L.C.$269
  • Johnson & Johnson$207
  • Boston Scientific$103
  • Novo Nordisk$94
  • Pfizer$57
  • plus $266 from 11 others

What the payments were for

  • Food & beverage$1,93598%
  • Education$462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,980 in reported general payments places this provider in the 30th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$311,411
Medicare patients
1,343
Services billed
5,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban820$667,380
EntrestoSacubitril/Valsartan266$254,352
JardianceEmpagliflozin103$104,596
XareltoRivaroxaban78$76,406
Repatha SureclickEvolocumab71$44,794
Praluent PenAlirocumab34$19,444
BrilintaTicagrelor30$18,634
Metoprolol Succinate894$13,339
Potassium Chloride390$6,274
Atorvastatin Calcium559$4,669
Nebivolol Hcl84$4,653
Losartan Potassium505$4,495
Olmesartan Medoxomil270$3,689
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide91$2,966
Amlodipine Besylate552$2,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$667,380820 claims
NovartisEntresto$986$254,352266 claims
Johnson & JohnsonXarelto$207$76,40678 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →